Investor Presentaiton

Opdivo (anti-PD1) Lung Cancer Trials Indication Phase/Study # of Patients Design Endpoints Status CT Identifier Oncology Hematology Cell Therapy Immunology Cardiovascular Peri-Adjuvant NSCLC Stage IB-IIIA Adjuvant NSCLC Stage III Unresectable NSCLC Phase III CheckMate -77T N = 452 Neoadjuvant Opdivo 360mg + PDCT Q3W for 4 cycles followed by adjuvant Opdivo 480mg Q4W for 1 year Neoadjuvant placebo + PDCT followed by placebo Primary: EFS • Key secondary: OS Positive topline results in September 2023 Data presented at ESMO 2023 as a Late Breaker in the Presidential Symposium NCT04025879 • Phase III ANVIL Non-BMS Sponsored* Opdivo Q4W N = 903 Observation (patients followed serially with imaging for 1 year) • Primary: DFS, OS Phase III CheckMate -73L N = 888 Opdivo + CCRT followed by Opdivo + Yervoy Opdivo + CCRT followed by Opdivo CCRT followed by durvalumab • Primary: PFS • Key secondary: OS • Projected data readout 2025 • Projected data readout 2024 NCT02595944 NCT04026412 ll Bristol Myers Squibb Q3 2023 Results *Trial conducted by NCI/ECOG Not for Product Promotional Use 32

View entire presentation